Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

12 Issues per year

IMPACT FACTOR 2014: 2.707
Rank 6 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046



Study of Therapy Resistance in Cancer Cells with Functional Proteome Analysis

Julia Poland / Dirk Schadendorf / Hermann Lage / Martina Schnölzer / Julio E. Celis / Pranav Sinha

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 40, Issue 3, Pages 221–234, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2002.037, June 2005

Publication History

Published Online:


Different types of cancer are naturally resistant to many anticancer drugs. Additionally, these tumours develop acquired drug resistance, which includes the classical multidrug resistance (MDR) accompanied by the synthesis of P-glycoprotein, a member of the superfamily of ATP-binding cassette (ABC) transporters. Furthermore, atypical MDR is mediated by several different, some unkown, mechanisms. To overcome chemoresistance problems, antineoplastic drugs are often combined with other modes of therapy, e.g. hyperthermia, where good response has been reported in several experimental tumour models and in advanced cancer patients. The success of this combined anticancer treatment may be limited by an increase in chemoresistance and thermoresistance.

A model system to study resistance phenomena is the use of chemoresistant and thermoresistant cancer cell lines. We have established chemoresistant cancer cell lines (gastric and pancreatic carcinoma, fibrosarcoma, melanoma) and now thermoresistant cell lines derived from gastric and pancreatic carcinoma cells and their counterparts that were resistant towards daunorubicin (classical MDR) and mitoxantrone (atypical MDR).

Using proteomics, in this paper we evaluate the drug resistance of chemoresistant melanoma cells (parental cell line MeWo and sublines exhibiting drug resistance towards etoposide, cisplatin, fotemustine and vindesine) as a paradigm for analysis of drug resistance phenomena. Additionally, we investigate heat resistance and the interaction of chemoresistance and thermoresistance to identify common pathways using the parental and drug resistant stomach cancer cell lines EPG85-257, EPG85-257RNOV, EPG85-257RDB and their thermoresistant counterparts. Possible implications of differential protein expression will be discussed.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Mirna Z. Bulatović, Danijela Maksimović-Ivanić, Christian Bensing, Santiago Gómez-Ruiz, Dirk Steinborn, Harry Schmidt, Marija Mojić, Aleksandra Korać, Igor Golić, Damian Pérez-Quintanilla, Miljana Momčilović, Sanja Mijatović, and Goran N. Kaluđerović
Angewandte Chemie, 2014, Volume 126, Number 23, Page 6092
X Peng, G Xie, Z Wang, H Lin, T Zhou, P Xiang, Y Jiang, S Yang, Y Wei, L Yu, and Y Zhao
Cell Death and Disease, 2014, Volume 5, Number 3, Page e1143
Matthias Löhr and Ralf Faissner
Pancreatology, 2004, Volume 4, Number 2, Page 67
Kazuya Arai, Ruriko Sakamoto, Daisuke Kubota, and Tadashi Kondo
PROTEOMICS, 2013, Volume 13, Number 15, Page 2351
Witold Szaflarski, Patrycja Sujka-Kordowska, Radosław Januchowski, Karolina Wojtowicz, Małgorzata Andrzejewska, Michał Nowicki, and Maciej Zabel
Biomedicine & Pharmacotherapy, 2013, Volume 67, Number 6, Page 497
Hermann Lage
Pathology - Research and Practice, 2004, Volume 200, Number 2, Page 105
Emma Niméus, Johan Malmström, Anders Johnsson, György Marko-Varga, and Mårten Fernö
Journal of Pharmaceutical and Biomedical Analysis, 2007, Volume 43, Number 3, Page 1086
Manimalha Balasubramani, Chitose Nakao, Guy T. Uechi, John Cardamone, Kathy Kamath, Kristen L. Leslie, Raghavan Balachandran, Leslie Wilson, Billy W. Day, and Mary Ann Jordan
Mutation Research/Genetic Toxicology and Environmental Mutagenesis, 2011, Volume 722, Number 2, Page 154
Ying Huang and Wolfgang Sadée
Drug Discovery Today, 2003, Volume 8, Number 8, Page 356
Simone Mocellin, Carlo Riccardo Rossi, Pietro Traldi, Donato Nitti, and Mario Lise
Trends in Molecular Medicine, 2004, Volume 10, Number 1, Page 24
Xingchen Peng, Fengming Gong, Gang Xie, Yuwei Zhao, Minghai Tang, Luoting Yu, and Aiping Tong
Molecular and Cellular Biochemistry, 2011, Volume 351, Number 1-2, Page 233
Pier Giorgio Righetti, Annalisa Castagna, Paolo Antonioli, Daniela Cecconi, Natascia Campostrini, and Sabina Carla Righetti
Expert Review of Proteomics, 2005, Volume 2, Number 2, Page 215
Peter Findeisen, Teresa Peccerella, Michael Neumaier, and Dirk Schadendorf
Expert Review of Dermatology, 2008, Volume 3, Number 2, Page 209
Wan Yen Lee, Peter Peng Foo Lee, Yaw Kai Yan, and Mathew Lau
Metallomics, 2010, Volume 2, Number 10, Page 694
Hermann Lage
PROTEOMICS - CLINICAL APPLICATIONS, 2009, Volume 3, Number 8, Page 883
Rosalyn D. Blumenthal and David M. Goldenberg
Molecular Biotechnology, 2007, Volume 35, Number 2, Page 185
José Bermúdez-Crespo and José Luis López
PROTEOMICS – CLINICAL APPLICATIONS, 2007, Volume 1, Number 9, Page 983
Comparative and Functional Genomics, 2002, Volume 3, Number 6, Page 551
Rachel A. Craven, Anthea J. Stanley, Sarah Hanrahan, Nick Totty, David P. Jackson, Razvan Popescu, Allen Taylor, J�rgen Frey, Peter J. Selby, Poulam M. Patel, and Rosamonde E. Banks
PROTEOMICS, 2004, Volume 4, Number 12, Page 3998
Holger T�nnies, Julia Poland, Pranav Sinha, and Hermann Lage
International Journal of Cancer, 2003, Volume 103, Number 6, Page 752

Comments (0)

Please log in or register to comment.